Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 4.47% | |
| Multiple of Ten Bullish | Other | 4.47% | |
| Below Lower BB | Weakness | 4.47% | |
| Down 3 Days in a Row | Weakness | 4.47% | |
| Lower Bollinger Band Touch | Weakness | 4.47% | |
| Oversold Stochastic | Weakness | 4.47% | |
| MACD Bearish Signal Line Cross | Bearish | 0.10% | |
| Multiple of Ten Bearish | Other | 0.10% | |
| Below Lower BB | Weakness | 0.10% | |
| Lower Bollinger Band Touch | Weakness | 0.10% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Up 5% | about 2 hours ago | |
| Up 1 ATR | about 2 hours ago | |
| Rose Above Previous Day's High | about 2 hours ago | |
| Outside Day | about 2 hours ago | |
| Up 3% | about 3 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/23/2021
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Oncology Chemical Compounds Lymphoma Small Cell Lung Cancer Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Solid Tumors Oncology Chemical Compounds Lymphoma Small Cell Lung Cancer Non Small Cell Lung Cancer Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 249.42 |
| 52 Week Low | 66.01 |
| Average Volume | 395,954 |
| 200-Day Moving Average | 172.05 |
| 50-Day Moving Average | 209.27 |
| 20-Day Moving Average | 202.00 |
| 10-Day Moving Average | 198.12 |
| Average True Range | 9.10 |
| ADX | 17.45 |
| +DI | 14.09 |
| -DI | 34.16 |
| Chandelier Exit (Long, 3 ATRs ) | 187.14 |
| Chandelier Exit (Short, 3 ATRs ) | 206.84 |
| Upper Bollinger Band | 216.42 |
| Lower Bollinger Band | 187.57 |
| Percent B (%b) | -0.23 |
| BandWidth | 14.29 |
| MACD Line | -4.66 |
| MACD Signal Line | -3.35 |
| MACD Histogram | -1.3058 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 195.20 | ||||
| Resistance 3 (R3) | 196.29 | 192.65 | 192.83 | ||
| Resistance 2 (R2) | 192.65 | 189.03 | 192.10 | 192.04 | |
| Resistance 1 (R1) | 186.83 | 186.80 | 185.01 | 185.73 | 191.25 |
| Pivot Point | 183.19 | 183.19 | 182.28 | 182.64 | 183.19 |
| Support 1 (S1) | 177.36 | 179.57 | 175.54 | 176.27 | 170.75 |
| Support 2 (S2) | 173.72 | 177.34 | 173.17 | 169.96 | |
| Support 3 (S3) | 167.90 | 173.72 | 169.17 | ||
| Support 4 (S4) | 166.80 |
